Tergus Pharma has acquired EnDev Laboratories, a Dermatology-centric CRO based in Kannapolis, NC. The acquisition will add extensive early-phase drug development capabilities from lead compound selection to skin biology.

Founded in 2016, EnDev will provide a synergy to consolidate Tergus’ growth in dermatological R&D, and significant skin biology research capability that includes skin irritation, skin sensitization, and drug activity testing using healthy or genetically-modified In Vitro and/or in Ex Vivo human skin models. The EnDev team also brings tremendous experience and knowledge in in early safety screenings, drug delivery and early drug metabolism and pharmacokinetic (DMPK) studies, product development, manufacturing support, and consulting services.

Tergus is a full-service CRO for topical pharmaceutical research & development, testing and cGMP manufacturing in a state-of-the-art facility in Durham, NC. 

“This acquisition completes a remarkable end-to-end portfolio and reinforces Tergus’ commitment to providing superlative CRO services on a global scale” said Vijendra Nalamothu, Ph.D., the chief executive officer of Tergus Pharma. He added, “It is an exceptional opportunity for clients to access a comprehensive suite of solutions built from the combined excellence and expertise of both companies.”

A wholly owned subsidiary of Tergus, EnDev will operate under its current leadership.